25 October 2019
LEI No. 213800QIPVTK5ES5UU36
Scapa Group plc
Notice of Results
Scapa Group plc (AIM: SCPA) announces that it will report its half-year results for the period ended 30 September 2019 on Tuesday 19 November 2019.
For further information:
|
Scapa Group plc |
Heejae Chae - Group Chief Executive Oskar Zahn - Chief Financial Officer
|
Tel: 0161 301 7430 |
|
Numis Securities Limited (Nominated Adviser/Joint Broker)
|
Mark Lander, Freddie Barnfield |
Tel: 020 7260 1000 |
|
Berenberg (Joint Broker)
|
Chris Bowman, Toby Flaux
|
Tel: 020 3207 7800 |
|
FTI Consulting (Media Relations)
|
Brett Pollard, Victoria Foster Mitchell |
Tel: 020 3727 1000 |
About Scapa Group plc
Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.
Healthcare
Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.
For further information, please visit www.scapahealthcare.com
Industrial
Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.
For further information, please visit www.scapaindustrial.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
